Orexigen Therapeutics (OREX) Earning Somewhat Favorable Press Coverage, Report Finds
News articles about Orexigen Therapeutics (NASDAQ:OREX) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.7443249536002 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 (finance.yahoo.com)
- Anti-Obesity Drugs Market | Key Trends and Forecast Research Report 2024 (openpr.com)
- Statins and Glucose Metabolism: Are All Agents Alike? (medscape.org)
- Focus on Momentum Mover: Orexigen Therapeutics, Inc. (OREX) – Wall Street Morning (wallstreetmorning.com)
- Investors Set Sail on Valuation For Orexigen Therapeutics Inc (OREX) – Wall Street Review (thewallstreetreview.com)
Orexigen Therapeutics (OREX) traded up 2.11% during mid-day trading on Friday, reaching $2.42. The company’s stock had a trading volume of 83,258 shares. Orexigen Therapeutics has a 12 month low of $1.65 and a 12 month high of $5.70. The stock’s 50 day moving average is $2.52 and its 200 day moving average is $3.23. The company’s market cap is $37.34 million.
Orexigen Therapeutics (NASDAQ:OREX) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.40) by $0.58. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 120.77%. The company had revenue of $23.36 million for the quarter, compared to analyst estimates of $20 million. During the same quarter in the prior year, the company earned ($1.73) EPS. The firm’s revenue for the quarter was up 199.9% compared to the same quarter last year. Equities research analysts predict that Orexigen Therapeutics will post ($9.37) EPS for the current year.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Orexigen Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Monday, August 14th. ValuEngine downgraded shares of Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/26/orexigen-therapeutics-orex-earning-somewhat-favorable-press-coverage-report-finds.html.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Stock Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related stocks with our FREE daily email newsletter.